Recently, accumulating evidence demonstrated that SOX2 expression level is closely correlated with clinical progression and poor prognosis among various tumor types, including hepatocellular carcinoma [40], colorectal cancer [41], lung cancer [42], gastric cancer [21], and laryngeal squamous cell carcinoma [43]. This evidence concerns the gene SOX2 and hepatocellular carcinoma.